TapImmune to acquire Marker Therapeutics

US clinical-stage immuno-oncology company TapImmune (Nasdaq: TPIV) has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

The proposed transaction will be a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing.

The proposed merger remains subject to certain conditions, including that financing and the approval of TapImmune stockholders.